Table 2.

Association between patient demographic and clinical characteristics and sorafenib use, multivariable logistic regression (2007 and 2012 National Cancer Institute Patterns of Care data)^*

	Odds ratio (95% confidence interval)
Year of diagnosis
2007	ref.
2012	1.53 (0.87, 2.69)
Age at diagnosis
<50 years	ref.
50–59 years	1.49 (0.58, 3.82)
60–69 years	1.65 (0.70, 3.91)
≥70 years	1.15 (0.46, 2.88)
Sex
Male	ref.
Female	0.76 (0.45, 1.28)
Race/ethnicity
Non-Hispanic White	ref.
Non-Hispanic Black	1.89 (1.03, 3.46)
Hispanic	1.97 (0.88, 4.43)
Asian/other	1.84 (0.92, 3.72)
Marital status
Married/living as married	ref.
Other	0.71 (0.39, 1.27)
Insurance status
Private insurance	ref.
Medicare only	0.81 (0.33, 2.01)
Any Medicaid	0.67 (0.37, 1.23)
No insurance/unknown	0.35 (0.11, 1.12)
Median census tract income
USD ≤50,000/year	ref.
USD >50,000/year	1.50 (0.89, 2.55)
Hepatitis
Yes	ref.
No indication	1.01 (0.55, 1.84)
Cirrhosis
Yes	ref.
No indication	1.43 (0.85, 2.41)
Child-Pugh score
Class A	ref.
Class B	0.46 (0.27, 0.79)

^*Italics indicate p ≤ 0.05; all other values are nonsignificant with a p > 0.05.